PTCL Clinical Trial
Official title:
A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03900442 -
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
|
Phase 1 | |
Withdrawn |
NCT02757248 -
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
|
Phase 1 | |
Not yet recruiting |
NCT05238064 -
Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL
|
Phase 1/Phase 2 | |
Recruiting |
NCT03240211 -
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
|
Phase 1 | |
Recruiting |
NCT04747236 -
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
|
Phase 2 | |
Completed |
NCT03493451 -
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
|
Phase 2 | |
Recruiting |
NCT05967949 -
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
|
||
Recruiting |
NCT03884205 -
GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL
|